1. European Medicines Agency. EMA biosimilars in the EU. Information guide for healthcare professionals. Available at: https://www.ema.europa.eu/en/documents/leaflet/biosimilars-eu-information-guide-healthcare-professionals_en.pdf. Accessed 20 Aug 2022.
2. Weise M, Bielsky MC, Smet KD, Ehmann F, Ekman N. Biosimilars: what clinicians should know. Blood. 2012. https://doi.org/10.1182/blood-2012-04-425744.
3. European Medicines Agency. Guideline on similar biological medicinal products containing monoclonal antibodies—non-clinical and clinical issues. Available at: https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-similar-biological-medicinal-products-containing-monoclonal-antibodies-non-clinical_en.pdf. Accessed 20 Aug 2022.
4. US Food and Drug Administration. Guidance for Industry: scientific considerations in demonstrating biosimilarity to a reference product, Guidance for Industry. Available at: https://www.fda.gov/media/82647/download. Accessed 20 Aug 2022.
5. Stebbing J, Mainwaring PN, Curigliano G, Pegram M, Latymer M, et al. Understanding the role of comparative clinical studies in the development of oncology biosimilar. J Clin Oncol. 2020;38(10):1070-80. https://doi.org/10.1200/JCO.19.02953.